TABLE 3.
Collecting period (h) | Median (range) UBTb (reciprocal value) of indicated drug for:
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
E. coli ATCC 25922
|
K. pneumoniae
|
E. coli
|
S. aureus I
|
P. mirabilis
|
P. aeruginosa I
|
|||||||
FLX | PFL | FLX | PFL | FLX | PFL | FLX | PFL | FLX | PFL | FLX | PFL | |
0–6 | 512 (128–1,024) | 256 (128–1,024) | 512 (64–1,024) | 128 (64–512) | 32 (8–256) | 16 (4–128) | 128 (16–512) | 128 (64–512) | 256 (128–1,024) | 512 (256–1024) | 32 (16–128) | 16 (4–64) |
6–12 | 512 (64–1,024) | 128 (64–512) | 256 (64–1,024) | 128 (32–512) | 24 (4–256) | 16 (4–64) | 128 (16–512) | 128 (64–256) | 256 (64–1,024) | 512 (128–1,024) | 32 (8–128) | 16 (8–32) |
12–24 | 256 (32–1,024) | 128 (32–1,024) | 256 (16–512) | 128 (16–512) | 16 (4–64) | 8 (2–64) | 64 (4–256) | 128 (32–256) | 128 (64–1,024) | 512 (128–1,024) | 16 (4–32) | 8 (4–32) |
24–48 | 64 (32–512) | 64 (16–512) | 64 (16–256) | 32 (8–512) | 4 (0–32) | 4 (0–64) | 32 (2–128) | 64 (16–128) | 32 (32–256) | 128 (64–512) | 4 (2–16) | 2 (0–32) |
48–72 | 24 (4–128) | 24 (2–256) | 16 (2–64) | 16 (0–128) | 0 (0–8) | 1 (0–16) | 8 (0–16) | 16 (4–32) | 8 (4–32) | 64 (16–128) | 0 (0–4) | 0 0–8) |
72–96 | 8 (0–32) | 8 (0–128) | 3 (0–16) | 4 (0–32) | 0 | 0 (0–8) | 1 (0–4) | 4 (1–16) | 2 (0–8) | 16 (4–128) | 0 | 0 (0–4) |
96–120 | 0 (0–8) | 2 (0–32) | 0 (0–2) | 1 (0–32) | 0 | 0 (0–2) | 0 (0–8) | 1 (0–4) | 0 (0–2) | 4 (1–32) | 0 | 0 (0–1) |
120–144 | 0 (0–4) | 0 (0–64) | 0 (0–2) | 0 (0–32) | 0 | 0 | 0 | 1 (0–8) | 0 | 2 (0–32) | 0 | 0 |
144–168 | 0 (0–4) | 0 (0–32) | 0 (0–4) | 0 (0–16) | 0 | 0 | 0 | 0 (0–4) | 0 | 1 (0–32) | 0 | 0 |
Median (range) UBT (reciprocal value) of indicated drug for:
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
P. aeruginosa II
|
E. faecalis I
|
S. saprophyticus
|
E. faecalis II
|
S. aureus II
|
Streptococcus group B sp.
|
||||||
FLX | PFL | FLX | PFL | FLX | PFL | FLX | PFL | FLX | PFL | FLX | PFL |
16 (4–64) | 8 (4–32) | 16 (4–32) | 16 (0–32) | 32 (16–64) | 32 (8–64) | 8 (4–32) | 16 (4–32) | 4 (1–16) | 1 (0–8) | 8 (4–32) | 8 (4–16) |
8 (2–64) | 8 (4–32) | 16 (2–32) | 8 (0–16) | 24 (8–64) | 16 (8–64) | 8 (2–16) | 8 (4–16) | 2 (1–8) | 1 (0–4) | 8 (4–32) | 8 (2–16) |
8 (2–16) | 4 (2–16) | 8 (2–16) | 8 (0–16) | 16 (4–32) | 32 (8–32) | 4 (2–8) | 4 (2–16) | 2 (0–2) | 1 (0–2) | 6 (2–16) | 8 (0–16) |
2 (0–16) | 2 (0–16) | 2 (0–4) | 2 (0–8) | 4 (2–8) | 8 (4–16) | 1 (0–4) | 2 (0–8) | 0 (0–2) | 1 (0–1) | 2 (0–4) | 2 (0–4) |
0 (0–2) | 0 (0–4) | 0 (0–1) | 1 (0–2) | 0 (0–2) | 2 (8–8) | 0 (0–1) | 0 (0–2) | 0 (0–1) | 0 (0–1) | 0 (0–2) | 0 (0–2) |
0 | 0 (0–4) | 0 | 0 (0–1) | 0 | 1 (0–2) | 0 | 0 (0–1) | 0 | 0 (0–1) | 0 (0–2) | 0 (0–2) |
0 | 0 (0–1) | 0 | 0 | 0 | 0 (0–1) | 0 | 0 | 0 | 0 | 0 (0–1) | 0 (0–2) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0–1) | 0 (0–1) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0–1) | 0 |
Dilution with antibiotic-free urine
Values in boldface are those that are significantly (P < 0.05) different for the two treatment groups. Ranges with endpoints of 1,024 include values greater than 1,024.